Carbimazole
| Clinical data | |
|---|---|
| Trade names | Neo-Mercazole, Anti-Thyrox, etc. |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 85% |
| Elimination half-life | 5.3h |
| Excretion | Kidney >90% |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.040.762 |
| Chemical and physical data | |
| Formula | C7H10N2O2S |
| Molar mass | 186.23 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 122 to 125 °C (252 to 257 °F) |
SMILES
| |
InChI
| |
| (verify) | |
Carbimazole (brand names Neo-Mercazole, Anti-Thyrox, etc.) is used to treat hyperthyroidism. Carbimazole is a pro-drug as after absorption it is converted to the active form, methimazole. Methimazole prevents thyroid peroxidase enzyme from iodinating and coupling the tyrosine residues on thyroglobulin, hence reducing the production of the thyroid hormones T3 and T4 (thyroxine).
It is on the World Health Organization's List of Essential Medicines.[2]
- ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Retrieved 13 May 2022.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.